司美格鲁肽真实世界一年依从性与减重结局:合并减重手术史与否的比较
该回顾性研究纳入大型学术中心1,072例肥胖患者,评估司美格鲁肽真实世界一年依从性及总体重减轻百分比(%TWL)。1年依从率仅56.4%,全人群1年%TWL为8.8%,完成1年治疗者为10.9%;有Roux-en-Y胃旁路术(RYGB)史者%TWL高于无减重手术史者(13.6% vs 10.1%,P=0.022)。
要点
- 司美格鲁肽真实世界1年依从率仅56.4%,未启动与停药原因多与可及性和副作用相关。
- 全人群1年%TWL为8.8%,完成1年治疗者升至10.9%。
- 有RYGB史者%TWL高于无减重手术史者(13.6% vs 10.1%,P=0.022),袖状胃切除术者未见此差异。
核心结论
- 司美格鲁肽真实世界1年依从性低(56.4%),全人群1年%TWL为8.8%,完成1年治疗者为10.9%。
- 有RYGB史者使用司美格鲁肽的%TWL高于无减重手术史者,但袖状胃切除史者未见此差异。
研究设计与样本
- 回顾性系列研究,纳入大型多学科体重管理中心1,072例接受司美格鲁肽处方的肥胖患者。
- 主要终点为司美格鲁肽处方后1年内依从性和%TWL,并进一步评估有减重/代谢手术(MBS)史者的减重情况。
主要发现
- 1,072例中199例(18.6%)未启动司美格鲁肽,主要因可及性问题;268例(25%)在1年内停药,主要因患者因素和副作用。
- 全人群1年%TWL为8.8%[10.5],完成1年治疗者%TWL为10.9%[9.8]。
- 有MBS史者中,RYGB史者%TWL高于无MBS史者(13.6%[10.3] vs 10.1%[9.6],P=0.022),袖状胃切除史者未见差异。
- BMI>40者使用司美格鲁肽的%TWL低于BMI<40者。
临床怎么用
- 处方司美格鲁肽时应预估真实世界低依从性,并针对可及性与副作用进行管理。
- 对肥胖合并RYGB史患者,可预期司美格鲁肽带来更明显的体重下降。
局限性
- 回顾性设计,来自单中心多学科体重管理中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate weight loss outcomes of semaglutide in a real-world setting, specifically in patients who have undergone metabolic/bariatric surgery (MBS). SUMMARY BACKGROUND DATA: Despite excellent weight loss for semaglutide in clinical trials, actual results may be limited due to factors such as costs, drug availability, insurance coverage, and adverse events. METHODS: A retrospective series of patients with obesity prescribed semaglutide at a large multidisciplinary weight management center in a tertiary academic institution. Primary endpoints were compliance and percentage total weight loss (%TWL) within 1 year of semaglutide prescription, with further evaluation of weight loss in those with previous history of MBS. RESULTS: The average [SD] %TWL at 1 year among all patients prescribed semaglutide was 8.8% [10.5]. Of 1,072 patients prescribed semaglutide, 199/1072 (18.6%) did not start semaglutide mainly due to access issues, and 268/1072 (25%) discontinued it within 1 year primarily due to patient factors and side effects. Among patients who completed 1 year of treatment, %TWL was 10.9% [9.8]. In those with history of MBS, %TWL was higher in patients who underwent Roux-en-Y Gastric Bypass (RYGB), but not sleeve gastrectomy, compared to no MBS history (13.6% [10.3] vs. 10.1% [9.6]; P=0.022). Furthermore, %TWL with semaglutide was less in those with BMI>40, than those with BMI<40. CONCLUSIONS: 1-year semaglutide compliance is low at 56.4%. 1-year TWL for all patients prescribed semaglutide was 8.8%, and 10.9% for those who took semaglutide for 1 complete year. Patients who underwent RYGB tended to lose more weight with semaglutide than naïve MBS patients.
引用
- Medhati P, Shin TH, Wasden K, et al. GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery. Ann Surg. 2025. PMID: 40334053. doi:10.1097/SLA.0000000000006748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。